Denali Therapeutics Reports $124.1 Million Net Loss in Q2 2025, Increases R&D Investments

Denali Therapeutics Inc. reported a net loss of $124.1 million for the second quarter of 2025, compared to a loss of $99.0 million in the same period of 2024, marking a 25% increase in losses year-over-year. For the first half of 2025, the company recorded a net loss of $257.1 million, up from $200.8 million in the prior year. Total operating expenses for the second quarter were $135.0 million, a 16% increase from $116.6 million in the previous year, driven primarily by higher research and development costs, which rose by 12% to $102.7 million. General and administrative expenses also increased by 28% to $32.3 million, reflecting preparations for the potential commercial launch of its product candidates.

The company’s financial position showed a decrease in total assets, which fell to $1.17 billion as of June 30, 2025, down from $1.37 billion at the end of 2024. Cash and cash equivalents decreased to $141.2 million, while short-term marketable securities increased to $757.7 million, indicating a strategic shift towards liquid assets. Denali's accumulated deficit grew to $1.80 billion, reflecting ongoing investments in research and development without generating product revenue since its inception.

In terms of operational developments, Denali has made significant strides in its clinical programs. The company received Breakthrough Therapy Designation from the FDA for its lead product candidate, tividenofusp alfa (DNL310), aimed at treating MPS II (Hunter syndrome). The company is also advancing its collaboration with Biogen on the LRRK2 program for Parkinson's disease, with enrollment in the Phase 2b LUMA study completed. Additionally, Denali opened a new clinical biomanufacturing facility in Salt Lake City, enhancing its operational capabilities.

Denali's strategic focus includes expanding its portfolio of TransportVehicle™ (TV) based product candidates and advancing its clinical programs. The company has entered into a collaboration agreement with an unrelated third party, which will provide up to $75 million in funding for a Phase 2a study of BIIB122/DNL151. This funding is expected to offset some of the research and development expenses, which totaled $218.9 million for the first half of 2025, a 10% increase from the previous year. Looking ahead, Denali anticipates continued operating losses as it invests in its clinical pipeline and prepares for potential product launches, with a focus on securing additional funding to support its operations.